- GlobeNewswire•yesterdayTG Therapeutics Announces Orphan Drug Designation for TG-1101 for the Treatment of Neuromyelitis Optica and Neuromyelitis Optica Spectrum Disorder
NEW YORK, Aug. 26, 2016-- TG Therapeutics, Inc. today announced that the U.S. Food and Drug Administration has granted orphan drug designation for TG-1101 the Company’ s novel, glycoengineered anti-CD20 ...
- GlobeNewswire•3 days agoTG Therapeutics Announces Orphan Drug Designation for TGR-1202 for Treatment of Chronic Lymphocytic Leukemia
NEW YORK, Aug. 24, 2016-- TG Therapeutics, Inc. today announced that the U.S. Food and Drug Administration has granted orphan drug designation for the Company’ s oral, next generation PI3K Delta inhibitor, ...
TG Therapeutics, Inc. (TGTX)
NasdaqCM - NasdaqCM Real Time Price. Currency in USD
|Bid||5.63 x 200|
|Ask||6.74 x 100|
|Day's Range||6.17 - 6.60|
|52wk Range||5.41 - 15.06|
|1y Target Est||N/A|
Trade prices are not sourced from all markets
|P/E Ratio (ttm)||-5.04|
|Avg Vol (3m)||442,195|
|Dividend & Yield||N/A (N/A)|